/
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients lives. Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harn…
$3.52
$0.17 (-4.74%)
Live · 05:19 PM
The business is unprofitable at the operating level (-320.53% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 1.0%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -$99M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$35M
▲ +1.0% YoY
Net Income (TTM)
-$104M
▲ +0.3% YoY
Op. Margin
-326.56%
▲ +15.6pp YoY
ROIC
-33.87%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$96M
▼ -52.0% YoY
Op. Cash Flow (TTM)
-$95M
▼ -51.5% YoY
Net Debt
-$177M
Net Cash Position
Cash & Equiv.
$236M
3Y CAGR: +5.0%
Continue Research
C4 Therapeutics (CCCC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, C4 Therapeutics scores 33/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
C4 Therapeutics scores 33 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -326.6% operating margin and a -33.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CCCC's valuation and scores 33/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.